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INV ITED
P A P E R
The Integration of Positron
Emission TomographyWith
Magnetic Resonance Imaging
First-generation systems that combine these two techniques have been developed
offering new opportunities for integrated structural-functional imaging in vivo.
By Simon R. Cherry, Fellow IEEE, Angelique Y. Louie, and Russell E. Jacobs
ABSTRACT | A number of laboratories and companies are
currently exploring the development of integrated imaging
systems for magnetic resonance imaging (MRI) and positron
emission tomography (PET). Scanners for both preclinical and
human research applications are being pursued. In contrast to
the widely distributed and now quite mature PET/computed
tomography technology, most PET/MRI designs allow for
simultaneous rather than sequential acquisition of PET and
MRI data. While this offers the possibility of novel imaging
strategies, it also creates considerable challenges for acquiring
artifact-free images from both modalities. This paper discusses
the motivation for developing combined PET/MRI technology,
outlines the obstacles in realizing such an integrated instru-
ment, and presents recent progress in the development of both
the instrumentation and of novel imaging agents for combined
PET/MRI studies. The performance of the first-generation
PET/MRI systems is described. Finally, a range of possible
biomedical applications for PET/MRI are outlined.
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I . INTRODUCTION
Magnetic resonance imaging (MRI) and positron emission
tomography (PET) have established themselves as very
powerful and flexible imaging technologies. MRI provides
exquisite anatomic images, with high spatial resolution (as
good as tens of micrometers for preclinical studies and
1 mm for clinical studies) and excellent soft tissue contrast.
Image contrast can often be selectively enhanced utilizing a
range of passive contrast agents, some based on paramagnetic
atoms, particularly gadolinium [1], some on superpara-
magnetic iron oxide particles [2], and others on hyper-
polarized gases such as xenon [3].MRI can interrogate aspects
of physiology; for example, functional MRI (fMRI) takes
advantage of the physiologic consequences of neuronal
activation (the BBOLD[ effect) to visualize task-dependent
responses [4]. MRI is also capable of reporting on abundant
molecular targets and pathways through the use of a range of
targeted imaging probes and contrast mechanisms [5].
Finally, measurement of the chemical shifts in the resonance
signal of protons, as well as nuclides such as 31P and 19F,
allows the abundance of many interesting metabolic products
and mass levels of drugs to be detected. With magnetic
resonance spectroscopic imaging (MRSI), these compounds
can be mapped spatially [6], albeit at a relatively coarse scale
compared with the resolution of conventional anatomic MRI.
PET has tremendous flexibility in interrogating biologic
processes using a range of targeted probes that include
radio-labeled small molecules (e.g., receptor ligands,
enzyme substrates), peptides, antibodies, and cells [7],
[8]. With extremely high sensitivity, PET allows the quan-
titative imaging of even relatively low abundance targets
without introducing mass effects. PET radionuclides range
from short-lived biologically relevant isotopes such as
15OðT1=2 ¼ 2 minÞ and 11CðT1=2 ¼ 20 minÞ to the clinical-
ly ubiquitous 18FðT1=2 ¼ 110 minÞ and longer lived radio-
halogens and radiometals such as 64CuðT1=2 ¼ 12:6 hÞ,
76BrðT1=2 ¼ 16:1 hÞ, and 124IðT1=2 ¼ 4:2 dÞ. While the
sensitivity for detection is several orders of magnitude
better than MRI, the spatial resolution is significantly
inferior, ranging from around 1 mm for preclinical PET
scanners to 4–6 mm for human whole-body PET scanners.
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PET and MRI both utilize radiation that penetrates
tissue well; thus these techniques have translational appli-
cations that bridge from basic biological research and
preclinical studies in animal models to clinical research,
clinical trials, and diagnostic use in humans. As PET and
MRI occupy quite different positions in resolution/
sensitivity space, neither PET nor MRI alone is sufficient
to tackle the broad range of questions that might be of
interest in a research or diagnostic study. Therefore they
are often used in combination. Indeed, it is quite common
for both PET and MRI studies of a subject to be acquired on
separate scanners and then spatially coregistered through
advanced image alignment algorithms [9]. This has been
particularly effective in the brain, where tissue remains
relatively fixed in position because of the skull allowing
simple rigid body transformations to be used to align the
datasets with high precision. Outside the brain, however,
software registration of the two datasets is far from trivial
and typically requires elastic transformations to account for
differences in patient pose and changes in internal geo-
metry due to dynamic processes within the body (e.g.,
movement of stomach contents, filling of the urinary
bladder). Depending on the information content of the two
datasets, it may not be possible to accurately align such
studies. This raises the question as to whether an integrated
PET/MRI instrument that can simultaneously, or near
simultaneously, acquire the two datasets in a fixed geo-
metry might be a better solution. In addition to the obvious
advantage of facilitating precise anatomic localization of
signals detected in PET studies (the primary role for PET/
computed tomography (CT) scanners), such an instrument
would open up novel opportunities, for example, the
temporal correlation of PET and MRSI studies, the imaging
of two molecular targets simultaneously using distinct PET
and MRI imaging probes, or simultaneous high-sensitivity
(PET) and high-resolution (MRI) imaging of a target using
a single imaging probe that is both PET and MR visible.
In this paper, we discuss the challenges and obstacles
in developing PET/MRI instruments and review the
technologies being developed for integrated PET and
MRI scanners, focusing on an MRI-compatible PET insert
developed at the University of California, Davis, in
collaboration with the California Institute of Technology.
We then discuss the development of novel dual-modality
targeted contrast agents that could be used with such a
system. Finally, we speculate on some of the applications
for such a device, in both the clinical and the preclinical
arenas, and outline remaining opportunities and chal-
lenges that still need to be addressed.
II . INTEGRATED PET/MRI SYSTEMS
A. General Considerations
Some of the essential features of an MRI scanner
are: i) a high and extremely homogeneous (typically a
few ppm) main magnetic field usually in the range of
1.5–11.7 T; ii) smaller magnetic field gradients (typical
ranges of 20 to 100 mT/m) that are applied across the
imaging field of view and that are rapidly switched on and
off; and iii) relatively high power radio-frequency pulses
that are used to excite the sample at the resonance fre-
quency of the nuclei of interest. For protons, this ranges
from 64 MHz at 1.5 T to 500 MHz at 11.7 T.
PET scanners typically consist of annular arrays of
scintillation detectors, where the 511 keV annihilation
photons resulting from þ (positron) decay are converted
into visible light by interaction in dense, fast scintillator
materials, and this scintillation light is then converted to
an electrical signal, commonly using a photomultiplier
tube (PMT). By way of example, the scintillator lutetium
oxyorthosilicate (LSO) emits on the order of 12 000
photons centered around 420 nm when 511 keV of energy
is deposited. Depending on the geometry and surface
treatment of the scintillator and the application of external
reflectors, something on the order of 20%–60% of the
scintillation light photons reach the photocathode of the
PMT, where, with a quantum efficiency of roughly 20% at
420 nm, several hundred photoelectrons are typically
produced. This signal is amplified by a factor of roughly
106 by the PMT, producing a transient current in the
milliamp range at the PMT anode. A PET scanner may
consist of many thousands of scintillator detector ele-
ments, read out by tens or hundreds of PMTs.
In integrating these two imaging technologies, several
possible impediments immediately come to mind. A PET
scanner within or close to the magnet could interfere with
the ability to acquire MR data by disturbing the homo-
geneity of the main magnetic field or the linearity of the
gradient fields beyond the level that can be accurately
corrected by shimming. If components of the PET scanner
are placed within the magnet, then susceptibility artifacts
caused by the materials comprising these components, or
the possibility of eddy currents being generated in these
components, become a concern. Another critical area to
consider is RF radiation emitted by the PET scanner elec-
tronics, particularly if there is any significant power ra-
diated at the resonance frequencies of interest that would
interfere with the MR measurement. There also are a
number of mechanisms by which the MRI scanner might
interfere with PET data acquisition. This includes the
effect of the main magnetic field and gradient fields on the
photodetector that is used to read out the scintillator. It is
worth noting that PMTs are particularly susceptible to
magnetic fields, with most PMTs showing significant gain
changes in fields as modest as a few milliTesla. The gen-
eration of eddy currents in critical components of the PET
pulse processing pathway, and RF interference caused by
rapid changing of gradient fields or pulsing of RF exci-
tation, could also destroy the low-amplitude PET signals.
These considerations demonstrate that a functional
integration of these two modalities, with performance
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consistent with standalone PET or MRI devices, is
challenging. Nonetheless, over the past decade, there has
been considerable progress as will be described below.
There are two main geometries one can consider in
combining PET and MRI into a single imaging system
(Fig. 1). In the tandem configuration, a PET scanner may
be placed just outside the magnet, and PET/MRI imaging
would be accomplished by moving the patient sequentially
through the two imaging devices. This is typically the
geometry used in clinical PET/CT scanners. The advantage
of this configuration is that by separating the two systems
axially, possible interference can be minimized, the PET
scanner design is not subject to geometric constraints
imposed by the bore size of the MR system, and existing
PET and MRI systems might be able to be used with
relatively little modification. It is also likely the cheapest
way to realize PET/MRI systems and the approach least
likely to lead to compromises in image quality with either
modality. For all these possible advantages, it is interest-
ing to note that none of the PET/MRI scanners actually
built to date employs this approach. The second con-
figuration involves building a PET scanner within the bore
of the MR magnet. The advantages of this integrated
approach are that the PET and MRI systems view the
same region of the subject and, if interference is eli-
minated, simultaneous PET/MRI imaging is possible. This
is attractive from a number of perspectives. In considering
clinical applications, it dramatically improves throughput
(both PET and MRI are relatively slow imaging tech-
niques compared with CT) and, for research applications,
it opens up enticing prospects of temporally correlating
dynamic PET studies with contrast (with passive or
targeted agents) MR studies or MR spectroscopy. How-
ever, the technical challenges are now significant. The
PET scanner must be reengineered to fit within the bore
of the magnet, interference between PET and MR systems
that are colocated must be negligible, and compromises in
imaging performance of one or both modalities become a
major concern.
B. Early Concepts: Effects of High Magnetic Fields
on Positron Range
The concept of performing PET studies within a high-
field magnet dates back at least to the early 1990s, when
Hammer and colleagues [10], [11] studied the effect that a
high static magnetic field would have in reducing the range
of positrons prior to their annihilation. PET images
actually reflect the spatial distribution of the positron
annihilation sites within the body, and this differs from the
site of radioactive decay (and therefore the location of the
radio-labeled molecule) by the distance the positron
travels prior to annihilation. The positron range depends
on the energy distribution of the emitted positrons, and
this varies widely between positron-emitting radio-
nuclides. When imaging high-energy positron-emitting
radionuclides on very high-resolution PET scanners,
positron range can be a limiting factor in the achievable
spatial resolution. Placing the sample in a strong magnetic
field constrains the positron travel in the plane perpen-
dicular to the magnetic field lines and, therefore, reduces
positron range in two of three dimensions. MRI scanners
are a natural and available source for such a strong mag-
netic field, and the concept of PET/MRI was therefore
explored. A number of experimental studies and Monte
Carlo simulations have studied this effect [11]–[13], and
for fields above 4.7 T and radionuclides such as 15O, 68Ga,
and 82Rb, the effects can be significant (Fig. 2). However,
for the most commonly utilized PET radionuclides 18F and
11C, the effects are small because they emit relatively low-
energy positrons. The effects of positron range are likely
only seen in the very highest resolution preclinical PET
scanners, and even here, they are generally still not the
dominant source of resolution loss [14].
Fig. 1. Two possible geometries for combined PET/MRI scanners.
(a) The ‘‘tandem’’ configuration is similar to most PET/CT scanners in
that the two scanners are axially displaced and PET and MRI studies
would be acquired sequentially. (b) The ‘‘integrated’’ configuration
involves placing the PET scanner within the magnet such that the
same region can be imaged by PET and MRI simultaneously.
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C. First Attempts at Simultaneous PET/MRI Imaging
The magnetic field sensitivity of the PMTs used in most
PET detectors was well known, and therefore the earliest
attempts at detecting PET radionuclides within a magnet
focused on using light guides placed in between the
scintillator and the PMT. The purpose of the light guide was
to pipe scintillation light from scintillator crystals placed
within the MRI scanner to shielded PMTs, placed outside
the magnet in a location where the fringe field had dropped
to levels low enough for operation [15], [16]. A system that
allowed the detection of total radiotracer activity within an
object placed inside of a nuclear magnetic resonance
(NMR) spectrometer was developed, allowing dynamic
radio-assay studies to be performed concurrently with
NMR spectroscopic measurements [16]. However, this
system provided no spatial information regarding the
distribution of the radiotracer within the object.
By replacing the light guides with flexible optical
fibers, and paying careful attention to maximizing
scintillation light collection and transmission along the
fiber, it became possible to consider placing larger
numbers of scintillation detectors within the bore of the
magnet, providing sufficient sampling for images to be
produced. The first MR-compatible PET system had a
single ring of just 48 LSO scintillators, and with a bore
size of 3.8 cm could only be used for imaging small test
objects. Nonetheless, it did demonstrate for the first
time that PET and MR images could be acquired simul-
taneously with little apparent interference between the
two systems [17]. A subsequent version [18] increased
the number of scintillator elements to 72 and had a
bore size appropriate for small animal and isolated
organ imaging (Fig. 3). This system was extensively
used for temporally correlated PET and NMR measure-
ments of isolated perfused rat hearts at 9.4 T [19], and
a series of phantom studies demonstrated the lack of
any significant interference when conducting simulta-
neous PET and MRI studies at several different field
strengths [20].
D. PMT-Based PET Systems Inside Existing
MRI Scanners
While these very first systems were sufficient for proof-
of-concept studies, they had significant limitations in
terms of their PET performance for routine in vivo use. In
particular, the sensitivity of the devices (the fraction of
radioactive decays leading to a valid coincidence event)
was very low because of the small number of detectors.
Furthermore, the long optical fibers attenuated much of
the scintillation light, reducing the energy and timing
resolution of the PET measurement. Recently, a higher
density system has been constructed along similar lines
with 416 detectors, improving resolution uniformity and
sensitivity of the PET insert relative to earlier attempts
[21]. This PET insert, however, is still limited to producing
a single transverse slice through the object. PMT-based
approaches using long optical fibers have also been used to
obtain limited angle tomographic PET images simulta-
neously with MRI in vivo [22].
E. Novel MRI Scanner Designs for PET/MRI
The methods discussed so far have involved designing a
PET insert to fit within existing MRI systems. An alter-
native approach is to change the design of the MR system
so that it can better accommodate the detectors comprising
a PET system. Two different ideas that involve modifica-
tion of the MRI magnet are currently being pursued.
The first utilizes a split magnet design [23], where the
PET detectors will reside in the gap between the magnets
(Fig. 4). The PET detectors still consist of scintillator
elements coupled through long optical fibers to PMTs;
however, in this configuration, the fiber optics emanate
radially from the magnet, allowing many more PET
Fig. 2. Monte Carlo simulation showing the effect of a 7 T magnetic
field on the trajectories and annihilation locations of 3 MeV positrons.
Reproduced with permission from [13].
Fig. 3. (a) Early MRI-compatible PET insert featuring (b) a ring of
72 LSO scintillator elements coupled via 3-m-long optical fibers to
multichannel PMTs. (c) First simultaneous in vivo PET andMRI images
acquired with this system. Adapted with permission from [139].
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detectors to be packed into the system [Fig. 4(b)]. This will
allow the sensitivity of the PET component to rival that of
standalone preclinical PET systems and provides imaging
of a full three-dimensional volume rather than an
individual slice. However, the loss of scintillation light
through the long optical fibers still compromises the
energy and timing resolution of the PET component (not
critical for preclinical imaging, but this could be a major
drawback for scaling up to humans), and the field strength
of the MR system is only 1.0 T, limiting perhaps some of
the more advanced MR applications one might be
interested in pursuing in combination with PET.
The second approach involves a novel field-cycled
magnet [24], [25] in which the polarizing and readout
magnetic fields can be rapidly cycled on and off, allowing
PET data acquisition to be interleaved with MR data
acquisition and to occur at times when the magnetic field
is zero. This permits PMTs to be used without long optical
fiber connections, avoiding the light losses described in
earlier designs. A further advantage is that the polarizing
field does not need to be homogeneous. However, the
effective sensitivity of the PET scanner is lower than the
absolute sensitivity because data can only be collected for a
certain fraction of the total acquisition time. Furthermore,
the field strength of the MR system is low, once again
limiting the range of possible MR applications.
F. Avalanche Photodiodes for PET/MRI
The problems created by the magnetic field sensitivity
of PMTs can be avoided by replacing them with avalanche
photodiodes (APDs). These silicon devices convert light
photons into electron-hole pairs that are then amplified by
a gain factor on the order of 100–1000. Because the charge
generation and multiplication take places in a very thin
layer of silicon, with a very high electric field across it,
electron trajectories are virtually unaffected by even very
high magnetic fields [26]. This makes them attractive for
PET/MRI systems. With improvements in their stability
and more widespread availability, several laboratories and
companies have been exploring their use. Challenges in
using APDs include the strong dependence of their gain on
temperature and bias voltage and their lower overall gain
compared with PMTs, which reduces signal amplitude and
generally requires preamplifiers to be placed immediately
adjacent to the devices.
In the PET insert recently developed at the University
of California, Davis, position-sensitive APDs (PSAPDs) are
used to read out LSO scintillator arrays using short optical
fiber bundles such that the PSAPDs and their readout
electronics reside within the bore of the magnet but
outside of the imaging field of view of the MRI (Fig. 5).
This 60 mm outer diameter insert has a total of 1024 LSO
elements with dimensions of 1.43 1.43  6 mm3 that
are arranged in eight rings and provides a field of view
(FOV) of 35 cm in the transverse direction and 12 mm in
the axial direction [27]. The spatial resolution of the
reconstructed PET images is 1.2 mm, and the sensitivity at
the center of the FOV is 0.3%. Phantom experiments
inside a Bruker 7.0 T/30 BIOSpec animal MRI system
demonstrate no significant effect of the PET insert on the
performance of the MRI system. Conversely, with the
exception of a very small drop in sensitivity (G 10%) that is
observed when running some pulse sequences, the MR
system has no observable effect of the PET system. This
small loss in sensitivity is likely due to a loss of PET data
during times when the gradients are rapidly switching.
More demanding MR pulse sequences, including echo
planar imaging (EPI), high-resolution MRI, and localized
spectroscopy have also been successfully conducted in the
presence of the PET insert. This PET system has now been
used for a range of in vivo imaging studies where MRI and
PET data are acquired simultaneously.
A similar approach has been taken by researchers at the
University of Tu¨bingen, except in this case, the optical
fiber connection has been completely eliminated and the
APDs and associated electronics are coupled directly be-
hind the scintillator arrays within the MRI field of view
[28]. Initial results from this system, including dynamic
PET and MRI measurements, also have clearly demon-
strated the feasibility of simultaneous PET and MR
imaging. APD approaches for preclinical PET/MRI are
also being investigated by others [29]. It remains to be seen
whether there is any advantage from the MRI perspective
of keeping the APD readout outside of the imaging field of
view or whether the fiber-optic coupling can be abandoned
for even the most demanding MRI measurements, which
Fig. 4. (a) Split magnet design for combined PET/MRI. (b) The PET
detectors will be located in the gap with the optical fibers emanating
radially as shown. (c) View of (front) a single PET detectormodulewith
scintillator array connected to (back) a position-sensitive PMT by
optical fibers. Adapted with permission from [23].
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would give the best possible performance from the PET
perspective.
All the systems discussed so far have been designed for
preclinical imaging, partly because there are significant
motivations for simultaneous PET/MRI studies in the
research setting and partly because the smaller volume of
detectors needed in the magnet for rodent imaging makes
this an attractive starting point. Recently, the first human
PET/MRI scanner has been developed by Siemens [30],
also using the APD approach, in a very similar detector
configuration to that in the preclinical system at the
University of Tu¨bingen. Impressively, the 35.5-cm-
diameter insert consists of 23 040 LSO scintillator
elements read out by 1440 APDs with an axial FOV of
19 cm (Fig. 6). This PET insert is installed in the Siemens
Trio 3 T scanner, and simultaneous in vivo PET and MR
imaging of the human brain has been demonstrated, with a
spatial resolution in the PET images of about 2.5 mm.
III . MULTIMODAL CONTRAST AGENTS
The use of multiple modalities for a common imaging
problem does not always require the use of multiple contrast
agents detected by each modality. Many reported studies use
combinations of PET with soft tissue contrast methods such
as CT and MRI, where the CT or MRI may be conducted
with or without contrasts agents. In this section, we provide
an overview of the application of contrast agents in
multimodality imaging studies. We first briefly review PET
imaging with MRI using combinations of contrast agents
and then highlight development of Bmultimodal[ agents
ranging from MRI/optical to PET/MRI.
A. Combined Modality Imaging With
Contrast Agents
The earliest research using multiple modalities was
performed primarily for the sake of validating one modality
Fig. 5. Photograph of (top) PET insert for preclinicalMRI scanner based on position-sensitive APD readout of 1.5 1.5  6 mm3 LSO scintillator
elements via short bundles of optical fibers. Lower photograph shows individual detector module. Adapted with permission from [27].
Fig. 6. Schematic and photograph of a PET insert developed for human brain imaging. Detectors are based on LSO scintillator
read out by arrays of APDs. (Courtesy of I. Panagiotelis, Siemens Medical Solutions.)
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through comparison with the other, rather than with the
intent of combining information. Nonetheless, these com-
parisons of multiple imaging modalities may have sparked
interest in using the imaging methods more synergistically.
Comparisons of PET performance with MRI for imaging of
brain tumors has been one of the most extensively reported
areas of study. MRI is routinely employed for morpholog-
ical imaging of brain tumors, typically with the use of a
gadolinium-based agent for contrast enhancement. Leak-
age of such a blood pool contrast agent through the
compromised neovasculature in the tumor creates areas of
enhanced contrast that demarcate the tumor vascular
boundaries. However, the condition and aggressiveness of
the tumor cells is not revealed by this method. Metabolic
information would be more diagnostic of tumor stage, but
the use of 18F-fluorodeoxyglucose (FDG) PET for imaging
brain tumors is not ideal, as normal brain tissue also has
very high levels of glucose metabolism; nevertheless, many
studies have demonstrated the utility of using FDG-PET to
stage tumors or assess the success of therapy [31]–[34].
Some of these comparative studies have discovered that the
different modalities yield complementary information,
thereby setting the stage for future work to further explore
this synergistic effect. For example, a recent study
comparing 18F-fluorothymidine (FLT) and 11C-methione
(MET) PET with gadolinium-enhanced MRI in patients
with glioma discussed the use of gadolinium-enhancedMRI
to determine the integrity of the blood-brain barrier, MET
to identify tumor invasion to neighboring tissue, and FLT,
with its longer half-life (relative to MET) for more accurate
assessment of cell proliferation [35]. Work in other disease
systems such as breast tumors [36], lymph node metastasis
[37], and inflammation [38], [39] has observed greater
accuracy for diagnoses based on the results of more than
one imaging method.
The brain applications described above all use clinically
approved gadolinium-enhanced contrast methods for
morphological characterization. In addition to the T1 and
T2 MR imaging methods used above, more quantitative
MR imaging methods can be employed to assess values
such as regional cerebral blood volumes (rCBVs). Brain
gliomas have been imaged with combinations of MET and
dynamic susceptibility contrast perfusion MRI to measure
rCBV [40]. In this application, both MRI and PET were
used to determine the proliferative and malignant
potential of gliomas and the results from each found to
closely correlate. MRI predicts tumor grade based on the
rCBV, which is higher in high-grade gliomas, while
MET-PET marks proliferating cells.
In addition to the use of MRI for simple anatomical
reference, the power and versatility of MRI to capture
dynamic information have also been exploited for com-
plementary imaging in conjunction with PET. Through the
use of appropriate imaging parameters, MRI can be tuned
to assess the dynamic movement of nuclei, i.e., diffusion,
in an image, thus providing time-dependent functional
information. This aspect of MRI has been widely used in
cardiovascular applications in conjunction with PET [41],
[42]. For example, PET and gadolinium-enhanced MRI
have been applied to assess defective glucose metabolism
in infarcted tissue and cardiac function, respectively, in
both animal models and human patients [43], [44]. The
results of the studies in rat models illustrate that MRI
measurements of scarring can complement FDG-PET
determination of myocardial viability to reveal the stage
of ischemic damage to the heart [43]. In the human pa-
tients, 15O-water PET was used to assess perfusion, while
delayed contrast enhancement cardiac MRI was used to
identify fibrotic tissue in patients with chronic myocardial
infarction [43]. The greater the amount of fibrosis and
lower the perfusion of tissue by water, the more severe the
disease stage. Both MRI and PET have been used to assess
myocardial viability [45].
The examples above have primarily treated the use of
multiple modalities as separate imaging methods and
compared images obtained by the various methods without
any attempt to overlay or spatially register the images.
With increasing interest in truly combining imaging
methods, there has been an increase in reports of co-
registered and simultaneously acquired, coregistered
imaging studies.
B. Fused PET and MRI Images Using Contrast Agents
Comparison of images between data sets obtained by
different imaging methods is considerably easier than
coregistering the images, but correlation of information
for diagnosis can require the greater accuracy of coregis-
tered methods. Methods to coregister data are a topic of
intense investigation and constant improvement [46],
[47]. Applications in the brain, for example, use coregis-
tration of images to precisely characterize drug uptake and
transport [48].
While applications in the brain for combined radio-
nuclide-based and MRI have been explored for years, a
newer application generating some excitement has been
cell tracking. Recent studies have used coregistered images
from 111In-SPECT [49] and MRI, or 124I-PET and MRI [50],
to track cell homing in cardiovascular and cancer appli-
cations, respectively. The SPECT/MRI studies use MRI to
provide anatomical mapping against 111In-oxyquinoline
labeled stem cells grafted to infarcted rat myocardium
while simultaneously acquiring 99 mTc-sestamibi maps of
perfusion deficient regions. The two radionuclide signals
were simultaneously acquired by using separate energy
windows. Fig. 7 shows the three coregistered images, with
stem cells and perfusion deficient regions mapping to the
akinetic region identified by MRI. In the discussion, the
authors comment on errors in coregistration that
occurred as a result of acquiring the MRI and SPECT
images several days apart, during which time the
myocardium was undergoing remodeling. Simultaneous
imaging with MRI and PET or SPECT would have
Cherry et al.: Integration of PET With MRI
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eliminated these errors and highlights the benefits for a
combined instrument that would allow simultaneous
multimodality acquisition.
C. Multimodality Contrast Agents
In the papers described up to this point, multimodal
imaging was achieved by using separate contrast agents for
each modality. The reports of multimodal, integrated
contrast agents that are detectable by more than one mo-
dality is a much more recent field, and by far the largest
number of reports are for single agents combining optically
detectable species with MRI detectable species. These
agents are paramagnetic (or ferromagnetic) and lumines-
cent with widely varying structures and composition.
Simple constructions of polymers or dendrimers coupled
to Gd and fluorescent dyes have been reported [51], [52],
as have more synthetically challenging combinations such
as a small molecule Gd-rhodamine fusion structure [51].
A very popular construct is to conjugate luminescent
quantum dots to other contrast agents. Gd coupled to the
surface of luminescence quantum dots [53] or super-
paramagnetic iron oxide particles (SPIO) coupled to
fluorescence dyes such as Cy5.5 have been reported by
many groups [54]–[58]. Another system, similar to the
commonly used secondary antibody amplification tech-
niques used in histology, employs a magnetically labeled
antibody in conjunction with a secondary antibody
labeled with a fluorescent dye [59].
More recently, efforts have been directed at fusing
different types of contrast agents. For example, SPIO has
been coated with a luminescent CdSe [60], or Yb or Er [61],
or silica dye infused layer [62]. Exotic heterostructures have
been reported containing combinations such as a quantum
dot with an FePt particle [63] or an FePt and Au particle
fusion [64]. In some of our work, we have reported Fe-Au
nanoparticles. The gold provides colorimetric bright field
contrast. One very complex design includes multiple layers
consisting of a silica core containing luminescent Ru(by)
coated with a Gd containing layer and an outer functiona-
lized silica layer [65]. Other work in our lab has focused on
developing quantum dots in which the paramagnetism is an
integral part of the quantum dot, and we have recently
reported development of Mn-doped CdSe-type quantum
dots and Si quantum dots. In recent work, we describe the
synthesis of core/shell CdSe/ZnxMn1xS nanoparticles [60].
As shown in Fig. 8, cells incubated with the nanoparticles
could be imaged by fluorescence microscopy and MRI.
Fig. 8(a) shows cells incubated with the dual-mode quantum
dots for one hour after washing and imaging by confocal
microscopy. Internalized quantum dots are clearly lumi-
nescing in the cytosol. The same cells were then lysed and
placed into tubes for MR imaging, shown in Fig. 8(b). Cells
Fig. 7. Coregistered SPECT/SPECT/MRI imaging MRI provides anatomical mapping (grayscale) against 111In-oxyquinoline labeled
stem cells (blue) grafted to infarcted rat myocardium and simultaneously acquired 99Tc-sestamibi maps (yellow) of perfusion deficient
regions. Reproduced with permission from [49].
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on the right show increased contrast after uptake of the
quantum dots.
There are very few examples of radio-labeled, multi-
modal imaging agents in the literature, but there is strong
interest in development of these types of tools, particularly
as multimodality imaging systems become more wide-
spread. The increasing interest in multimodal imaging has
led to development of systems to simplify the synthesis and
purification of multimodal agents, although strictly speak-
ing these are not necessary for all-in-one agents. For
example, Humblet et al. report an high performance liquid
chromatography (HPLC) system with multiple detection
elements for purification of agents for MRI, SPECT, PET,
radiotherapy or near-infrared optical imaging [66]. They
use an agent targeted to prostate-specific membrane
antigen coupled to 1, 4, 7, 10-tetraazacyclododecane-N,
N0, N00, N000-tetraacetic acid (DOTA) as an example. The
DOTA can hold Gd3þ for MRI, 111In, 185Re, or 99 mTc for
SPECT, or Y3þ for therapy. In their example, each molecule
holds only one DOTA and therefore is suited for only one
modality for imaging. But the idea of the HPLC system is
that it is capable of purifying any of the derivatives. This is
accomplished by connecting a nonradioactive subsystem,
containing separate mass spectrometry, absorbance, and
fluorescence detectors, to a radioactive subsystem with
beta and gamma detectors contained in a hot cell. Given the
great variation in sensitivities of the clinical imaging
modalities, it could be useful in certain applications to use
variants of the same imaging agent. However, there is no
guarantee that the signal will be coming from the same
location in coregistered images. In addition, the variants
will all compete for binding to the same target, and because
the lower sensitivity agents must be given in higher doses,
this may be an issue for labeling with the higher sensitivity
agents if they are delivered in a mixture. For these reasons
and others, it can be beneficial to have an agent carrying
multiple labels on a single molecule or particle.
An example of a true all-in-one multimodal agent
describes a single agent consisting of an Arginine-Glycine-
Aspartic Acid (RGD) peptide coupled to 111InDTPA and an
infrared (IR) dye that is targeted to integrin 3 receptors
[67]. The peptide 111InDTPA and near-IR (NIR) dye were
joined as shown in Fig. 9 and used to image human
melanoma xenografts in a nude mouse model. Fig. 10
shows the bright light, gamma, and luminescence images
from these mice. Fig. 10 shows images from mice after
(top) injections with the compound only or (bottom)
preinjection of RGD peptides followed by the compound
one hour later. In the image, the arrowhead refers to a
tumor in the hind leg generated from M21 while the arrow
Fig. 8. MRI of quantum dots in cells. (a) Cells internalize sufficient
multimodal quantum dots for detection by confocal microscopy.
Scale bar ¼ 20 ¼ 20 m. (b) Internalized quantum dots produce
MRI contrast. T1-weighted images from tubes containing cell
lysates. Reproduced with permission from [60].
Fig. 9. RGD peptide coupled to 111InDTPA and an IR dye.
Reproduced with permission from [67].
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indicates a tumor arising fromM21-L, which is negative for
the integrin receptor being targeted. The M2-L tumors do
not show enhancement by either modality, while the M21
tumors show enhancement by both NIR and -scintigraphy.
Preincubation with the peptide, partially blocked uptake
of the targeted agent. Fig. 10(b) shows an animal injected
with the NIR dye alone. The authors say that the level of
uptake is similar to mice that received the compound in
the presence of blocking agents. In their discussion, the
authors envision using this dual-mode probe to first vali-
date use of NIR probes in the clinic, and then in the
ultimate clinical application, the radiotracer will be used to
screen patients for cancerous lesions. Then, over time,
after the radiation has decayed, the optical part of the
probe could be used to guide subsequent biopsies or other
surgical procedures.
In work recently reported by our group, we have
generated gadolinium-based MRI contrast agents and iron
oxide-based probes that can be labeled with 64Cu for PET
imaging [68], [69]. These agents have potential for dual-
mode PET/MRI imaging of vascular inflammation. These
are targeted molecular imaging agents that will enable
in vivo assessment of macrophage accumulation associated
with cardiovascular disease. Macrophages express a
number of cell surface receptors, including class A types I
and II (SR-AI and II) and CD36 [70]–[72]. We target the
probes to macrophages through scavenger receptor type A
(SR-A) expressed by macrophages. We have selected SR-A
as a target as these receptors are expressed primarily by
macrophages; have not been found in normal aortic
endothelium; and are found in atherosclerotic lesions at all
stages [73]–[75]. The overall concept is to assess plaque
burden and vulnerability via multimodal imaging methods,
using the sensitivity of PET to identify putative lesions and
the resolution capability of MRI to assess plaque mor-
phology and macrophage density/distribution in plaques.
PET has the potential to survey large tissue volumes and
detect small but significant lesions; however, PET lacks
the resolution to fully visualize lesion structure. MRI
has the resolution to image vessel walls and report on
plaque composition but lacks the sensitivity to survey large
volumes for small lesions. MRI studies of carotid arteries
show promising results that support the feasibility of real-
time intravascular imaging but contrast-to-noise must be
improved before clinical use is possible. Contrast en-
hancement can be achieved through the use of exogenous
agents. Combining the high sensitivity of PET with the
high resolution of MRI through the use of a dual-mode
agent has the potential to enable both detection and
characterization of lesions in a single study.
D. Design of Dual-Mode PET/MRI Agents
We have designed two basic types of agents that are
either 1) polymer- or 2) nanoparticle-based. The basic
composition of both types of agents is a fusion of three
componentsVa targeting component, a paramagnetic
component that can be detected by MRI, and a positron-
emitting component for PET. In order to increase options
for MR imaging parameters, we have incorporated diverse
approaches to the problemVdifferent types of ligands
(protein, polynucleotide, and polysaccharide) with differ-
ent magnetic contrast mechanisms (T1 versus T2) were
generated. In the polymer agent, as shown in Fig. 11, the
polymer is the targeting component and consists of amino
acid or nucleotide polymers (mal-BSA, polyI, or polyG) that
are ligands recognized by macrophage scavenger receptors.
The polymer is conjugated to chelators that can hold either
paramagnetic gadolinium or 64Cu. The chelator selected,
DOTA binds strongly to either metal [76], [77]. The
nanoparticle agent in Fig. 12 consists of a paramagnetic
Fig. 10. NIR and SPECT images from human melanoma xenografts
in a rat model using the RGD-111InDTPA-IR dye construct.
Reproduced with permission from [67].
Fig. 11. Schematic of mal-BSA based dual-mode agent.
Gd (pink), Cu-64 (yellow).
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core of iron oxide that is coated by a layer of the targeting
polymer. The targeting polymer is a polysaccharide
(dextran sulfate) conjugated to DOTA chelating 64Cu.
The two types of agents differ in their mechanism of MRI
contrast. The polymer-based agents containing gadolinium
affect T1 relaxation times. T1 agents, such as gadolinium,
interact directly with water protons to shorten T1, which
results in an increase in signal intensity [78], [79]. The
nanoparticle-based agents containing iron oxides affect T2
relaxation times. T2 agents shorten T2 by a through-space,
magnetic field effect, resulting in a decrease in signal in-
tensity. Bothmethods enhance contrast by altering the signal
intensity of labeled tissue relative to neighboring tissues. T2
contrast agents are generally more sensitive and produce
effects at lower concentrations, while T1 contrast agents are
capable of greater dynamic range because they produce
positive contrast. Different contrast mechanisms may show
greater utility for particular types of imaging sequences or
tissue environments. By synthesizing both types of probes,
we have the greatest versatility to affect image contrast in any
system. Furthermore, the modular nature of the probes
allows us to expand to other imaging contrast mechanisms,
such as fluorescence, by attaching additional moieties.
E. Biomolecule-Based Probes
1) Targeting Macrophages via Scavenger Receptor SR-A:
We have previously shown that restenotic plaques can be
specifically labeled using a ligand to the macrophage sca-
venger receptor, namely, class A type scavengers (SR-A)
[80]. In these studies, a ligand to SR-A, maleylated bovine
serum albumin (mal-BSA), was labeled with a fluorescent
marker (Texas Red) and found to be specifically taken up
by cells in culture. Labeled mal-BSA was taken up by
macrophages but not by smooth muscle cells or endothe-
lial cells. This uptake was inhibited by excess unlabeled
mal-BSA, which supports a receptor-mediated mechanism
(not shown).
Further studies in the rat model showed that restenoses
occurring after balloon catheter deendothelialization were
brightly labeled by the fluorescent Texas Red mal-BSA
conjugates. In these investigations, abdominal aortas in
rats were denuded of intima by pulling an inflated balloon
catheter through three times. Two weeks after injury,
animals were injected with labeled mal-BSA or labeled
BSA as negative control. Four hours after administration of
the drug, abdominal aorta and uninjured thoracic aorta
controls were collected and prepared for cryohistology.
Frozen tissue sections were observed by fluorescence
microscopy. Fig. 13 shows (a) a labeling of the intimal
hyperplasia (IH) in an injured abdominal artery (b) that is
not observed in uninjured thoracic artery controls.
Additional controls, shown in Fig. 14, demonstrate that
labeling of IH occurs only (c) with mal-BSA and (a) not
with free dye alone or (b) labeled BSA.
These results suggest that ligands of SR-A can be used
as a delivery vehicle to shuttle labels to restenosis and
that perhaps other ligands or labels can be targeted to
Fig. 12. Design of dual-mode dextran sulfate coated nanoparticle.
Fig. 13. Fluorescent labeling of injured arteries. Injured arteries
(a) are labeled with Texas Red mal-BSA conjugates while
(b) uninjured arteries are not.
Fig. 14. Specific labeling of intimal hyperplasia. Injured arteries
were exposed to (a) Texas Red alone, (b) Texas Red-BSA conjugate,
and (c) Texas Red mal-BSA conjugate.
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restenoses in a similar manner. We have used two
different ligands of SR-A to localize dual-mode contrast
agents to restenoses for the purpose of noninvasive
imaging of plaques.
2) Mal-BSA Dual Mode PET/MRI Probe Synthesis: We
have synthesized and characterized a biomolecule-based
agent using the ligand maleylated bovine serum albumin
(mal-BSA) [68]. As illustrated earlier, this agent is
composed of mal-BSA conjugated to chelated Gd3þ,
paramagnetic ion for MRI contrast, and the radionuclide
64Cu for PET. We have demonstrated specific targeting of
this agent to macrophages in culture and performed
preliminary evaluations of the toxicity and biodistribution
of this agent. Here we summarize the results for this
agent.
BSA was maleylated by conjugating maleyl groups to
free amines by published methods [81]. Dual-mode agents,
detectable by PET and MRI, were generated by first
coupling the chelator p-isothiocyanatobenzyl-1, 4, 7, 10-
tetraazacyclo-dodecane 1, 4, 7, 10-tetraacetic acid (p-SCN-
Bz-DOTA) to remaining free lysines and then inserting the
metals; fortuitously either metal can be strongly coordi-
nated by this chelator [77], [82], [83]. MRI properties were
optimized before introduction of the radionuclide. T1
relaxivities for the mal-BSA based agents were comparable
to or better than the literature reported and commercial
agents.
3) Targeting of Mal-BSA Probe to Macrophages In Vitro:
The recognition and uptake of the probes by their target
macrophages were tested on cells in culture. To confirm
that uptake was specific, macrophages were incubated
with increasing concentrations of the mal-BSA based
agent, or a matched control agent that contained the same
number of Gd-DOTA groups but lacked the maleyl groups
required for recognition by the scavenger receptor. In
Fig. 15, the top row shows data from cells incubated with
mal-BSA(Gd-DOTA)22, the middle row contains BSA
ðGd-DOTAÞ22, and the bottom row is a pure water control.
As evident in the figure, there is no uptake of the labeled
BSA probe, while there is increasing signal intensity with
increasing concentrations of the mal-BSA agent as
expected.
In order to verify receptor-mediated uptake, cells were
incubated with a fixed concentration of labeled contrast
agent, 100 micromolar mal-BSA(Gd-DOTA)15, and in-
creasing excess of a matched unlabeled (no Gd) contrast
agent. In Fig. 16, we see that contrast enhancement is
reduced with increasing excess of competing unlabeled
contrast agent (from left to right, 0, 0.01, 0.1, 1, 2 mM
competitor, water blank). The numbers below each
image give the T1 value for the samples shown and
averaged over triplicate samples. Uptake that can be
competed away by unlabeled ligands is indicative of
receptor-mediated uptake. These studies demonstrated
that the agent can label macrophages for MRI contrast at
reasonable concentrations. Furthermore, cells were
imaged at densities of 3 105  2  106 cells/ml; this
is on the order of mean macrophage densities observed in
average human postmortem type IV–VI plaques
(3.5  104 macrophage/ml [85]).
For PET imaging, these mal-BSA agents were coupled
to 64Cu DOTA. In normal rats, the contrast agent
introduced by tail vein injections localized primarily in
the liver, kidneys, and spleen is as shown in Fig. 17. In
preliminary experiments in the balloon-injured rat model,
we found accumulation of contrast agent in the injured
vessel. Fig. 18 shows the PET signal from the mal-BSA
probe accumulated in an injured thoracic artery (upper
arrow). The spine and ribs (lower arrow) are clearly visible
in a serially acquired CT image that is coregistered with
the PET for anatomical reference. We have also been able
to image vessels walls by MRI (Fig. 19). These preliminary
images illustrate the promise for these dual-mode agents to
visualize macrophage accumulations in atherosclerotic
plaques.
Fig. 15. Uptake of macrophage targeted probe is specific.
Cells were incubated with (top) mal-BSA agent or (middle) Gd-DOTA
matched BSA control.
Fig. 16. Competition studies to verify specificity of uptake.
Cells were incubated with mal-BSA agent in presence of increasing
amounts of competing unlabeled mal-BSA.
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F. Nanoparticle Based Probes
1) Nanoparticle Synthesis: The designed dual-mode
nanoparticle-based probes consist of a core of iron oxide
coated with the scavenger receptor ligand dextran sulfate.
Iron oxide serves as the T2 MRI contrast agent, and for
PET, 64Cu (DOTA) is incorporated by conjugation to the
dextran sulfate surface. This is a one pot synthesis in which
Fe3þ and Fe2þ are mixed with reduced polysaccharide in
Fig. 17. Biodistribution of GdDOTA-64CuDOTA-mal-BSA 4 h after
tail-vein injection to normal rats localized primarily to liver, kidney,
and spleen.
Fig. 18. Thoracic aorta of rat damaged using balloon embolectomy
catheter through the carotid artery, imaged using PET/CT.
Fig. 19. Abdominal aorta T1-weighted MR image with cardiac gating.
Additional respiratory gating will improve image sharpness.
The abdominal/thoracic aorta is the smaller vessel in the center.
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the presence of base at low temperature, then gradually
heated and the particles spontaneously assemble. Briefly,
dextran sulfate coated particles were synthesized by
doping a small amount of dextran sulfate into a dextran
solution in the presence of iron chloride salts. More
detailed syntheses and modifications to the basic protocol
are described in our recent work on size-controlled
synthesis of these nanoparticles [69]. The relaxivity values
for the 5 wt% dextran sulfate doped particles [anionic
dextran iron oxide (ADIO)] were comparable to a
literature dextran coated iron oxide preparation (SPIO)
at 7 T [86]. Structural analysis by transmission electron
microscope (TEM) (Fig. 20) shows iron oxide cores of
5.2  1.3 nm in diameter. Overall hydrodynamic radius
determined by dynamic light scattering was 88.5 nm,
suggesting multiple cores per nanoparticle.
2) Targeting of Nanoparticle-Based Probes to Macrophage
In Vitro: The effect of dextran sulfate incorporation on
cellular uptake was explored using P388D1 macrophages.
Uptake of the ADIO particles by macrophages is greater
than uptake of plain SPIO. Dextran coated nanoparticles
can be nonspecifically phagocytosed by macrophages, but
receptor targeted dextran sulfate coating was anticipated
to increase iron uptake efficiency by macrophages.
Receptor mediated uptake is a more efficient process
than nonspecific pino- or phagocytosis. As shown in
Fig. 21, the T2 values for cells incubated with nanoparticles
in iron concentrations of 100 g/mL and greater are
significantly lower for the ADIO particles (blue points).
Images of suspensions of these cells by MRI, as shown in
Fig. 22, show greater decrease in signal with concentration
for the ADIO samples (top row) compared to the SPIO
samples (bottom row). This suggests that incorporation of
sulfate groups into the particle coating results in increased
uptake of iron oxide compared to dextran coating alone.
Labeling of the nanoparticles with positron-emitting ions
is achieved by coupling p-SCN-DOTA to the nanoparticles
through amine groups and inserting 64Cu.
One may surmise that reported multimodal agents only
hint at the future of the field, and MRI/optical agents have
had much more attention in recent literature. The
development of multimodal agents for combined PET/MR
imaging is still in its infancy, and there is still some
debate on the need for putting detectability by both
modalities on a single probe. When fused instruments
were proposed, these too were met with resistance. But
just as the benefits of fused instruments have revealed
themselves, multimodal agents have a place in the
diagnostic imaging repertoire. One can envision their
requirement in applications needing precise confirmation
that the signal detected by one modality is from the same
cellular or tissue source as the signal detected in another,
such as for guided biopsies. And as mentioned earlier, the
Fig. 20. TEM image of ADIO. Dextran sulfate coated iron oxide
nanoparticles have cores of 5.2 nm as determined by TEM.
Fig. 21. Cells incubated with targeted dual-mode agent show greater
decrease in T2 than cells incubated with nontargeted nanoparticles.
Fig. 22. T2 weighted images of cell lysate suspensions for
(a) ADIO and (b) SPIO. For both (a) and (b), from left to right, control,
25, 50, 100, 200, and 400 g Fe/mL. A significant decrease in
signal intensity for ADIO samples compared to SPIO samples is
seen. The images are from TE ¼ 375 ms of a multiecho spin echo
sequence. Parameters were TR ¼ 3200 ms, 75 ms echo spacing,
FOV ¼ 5.5 cm, matrix size 128  128, and slice thickness 1.2 mm.
The difference in diameter of the samples is due to the image plane
passing through different sections of the conical tubes.
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use of the differentially labeled agents with the same
molecule carrier can create an issue with competition by
the agent delivered in higher doses. Given the great dif-
ference in sensitivity between PET and MRI, the multi-
modal PET/MRI agent will essentially be a mixture of
dual-labeled agents and those with just MRI detectability.
But the added assurance that the signal from both modalities
comes from the same molecule can be advantageous.
IV. APPLICATIONS AND SPECULATIONS
As outlined in the introduction, the basic physical
underpinnings of PET and MRI are qualitatively different.
In PET, the three-dimensional location and concentration
of a positron-emitting compound are measured, often over
time, and provide the spatial intensity variations that make
up the PET image. The concentration of the compound at a
particular place at a particular time is a function of the
biological process or processes that the compound has
been designed to reflect (e.g., FDG reflects glucose
metabolism, FLT reflects cellular proliferation). In the
vast majority of MRI scans, the spatial intensity variations
that make up the MR image arise from differences in water
physicochemical properties and concentration of water
protons across the sample. For example, in the brain, white
matter, gray matter, ventricles, etc. (i.e., anatomical
structures) are distinguishable in an MR image because
the specific tissue characteristics perturb the local water
protons in different ways, giving rise to local differences
in water T1, T2 and/or density. Disease manifestations,
such as tumors and plaques, modulate tissue properties
(e.g., permeability, viscosity, cellularity, diffusion, tem-
perature, heterogeneity) and change MR characteristics
(e.g., T1, T2), making them visible in an MR image. As
discussed above, contrast agents play much the same role
in MRI as radionuclide labeled compounds in PET
imaging, although unlike PET radiotracers, they are not
observed directly but through their influence on nearby
water protons. It is the interplay between the direct and
the indirect, between the particular and the general, that
underlies both the utility and the fascination of simulta-
neous PET/MR imaging. In this section, we outline some
of the more obvious utilities of simultaneous PET/MRI
that have been confirmed in our preliminary studies and
detail speculations and expectations in three particular
applications that will serve as exemplars of how this
technology may be applied in future studies in a wide
variety of situations: imaging of brain function, mouse
phenotyping, and imaging of tumor biology.
A. Obvious Benefits
The most immediate benefit of the melded system is to
provide accurate and precise high-resolution anatomical
context for PET studies. The MRI and PET images are
Bautomatically[ in register because they are recorded at
the same time on the same sample with no sample
movement (other than that due to physiology). This may
seem rather trivial but, as discussed previously, image
registration for parts of a specimen that are not malleable
(e.g., brain) is not always straightforward, and for
malleable tissues is often very difficult. Fig. 23 shows
18F uptake into the bones of the skull, mouth, and jaw of a
mouse by PET, with no uptake into the brain or other
surrounding soft tissue. Although in this example uptake in
one tissue (bone) and not the adjacent tissue (brain) is
obvious, this will not always be the case. In experiments
aimed at tracking labeled cells (e.g., stem cells) introduced
intravenously, it will be crucial to differentiate between
cells in the vascular system and those taken up by specific
organs (lungs, spleen, bone marrow). In this case, accurate
and specific identification of the location of the PET label
by MRI will be essential for even rudimentary interpre-
tation of experimental outcome. Fig. 24 illustrates that
measures of the time dependence of FDG uptake and
simultaneous anatomical MRI are now straightforward
with the integrated PET/MRI systems described earlier.
Knowledge of the time dependence of the distribution of
labeled cells, complexes, and small molecules will be a
necessary part of determining their pharmacokinetics.
Thus, the ability to accurately coregister PET and MR
images without recourse to complex warping methods [87]
will be of tremendous importance in putting information
from PET scans in anatomical context in both preclinical
and clinical arenas.
Magnetic resonance spectroscopy (MRS) allows the
in vivo identification of specific chemical compounds.
1H MRS of the brain can be used to detect relative
concentrations of specific metabolites (e.g., glutamine,
N-acetylaspartate, creatine, choline) as a function of loca-
tion. Likewise, 31P MRS can be used to detect high-energy
phosphate metabolites (e.g., inorganic phosphate, ATP,
ADP, AMP). Information about relative amounts of metab-
olites and changes in them provide insight into physiolog-
ical changes in the tissues of interest. The use of 19FMRS to
follow the uptake, metabolism, and secretion of fluorinated
drugs takes advantage of the relatively high sensitivity of
19F in the MR experiment and the essential lack of any
background signal [88], [89]. Although of lower intrinsic
sensitivity, 13C MRS at natural abundance and with 13C
labeled compounds has proved useful in studies of
metabolic pathways [90]–[92]. It is natural to consider
applications of multilabeled 18F=19F or 11C=13C compounds
in which the high sensitivity of detection of PET is
combined with the ability of MRS to provide noninvasive
chemical analyses [93]. For example, the development/
discovery of Bprodrugs[ (compounds administered in an
inactive form that are subsequently metabolized in vivo
into the active therapeutic) will benefit greatly from the
ability to identify in vivo the site(s) and metabolic
processes that take the prodrug to its active form.
Fluoropyrimidines [5-fluorouracil (5FU)] are among the
oldest cancer chemotheraputics with several prodrugs in
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use or development (e.g., capecitabine and gemcitabine).
Preclinical PET/MRI studies using 18F=19F prodrugs will
point out where, when, and how the prodrugs are
metabolized along with determinations of drug efficacy.
This information is of critical importance in optimizing
prodrug performance. In the clinical setting, joint PET/MRI
examination will allow for individually optimized chemo-
therapy regimens.
The ability to quantitatively image time-dependent
changes in gene expression in vivo has significant potential
applications in developing and monitoring tissue specific
expression of a therapeutic gene. PET reporter gene
technologies rely on the binding or intracellular trapping
of a radio-labeled moiety [94]–[96]. Substrates useful in
other imaging modalites (SPECT, bioluminescence, and
fluorescence) may be simultaneously incorporated to make
a multimodal reporter gene construct [97], [98]. None of
these imaging modalities offers the soft tissue contrast or
physiological sensitivity of MRI. Thus, including MR will
provide indications of whether the gene expression is
actually altering the physiological state of the tissue and
supply anatomical context.
B. Brain Function
There is a long history of using both MRI and PET in
brain activation studies in human and small animal
model systems [99], [100]. Cerebral blood flow (CBF)
can be measured with PET using H152 O and with MRI
using bolus application of contrast agents [101]. Corre-
lates of neuronal activation are measured with PET by
Fig. 23. In vivo simultaneous PET/MRI: (a) PET images showing 18F ion uptake; (b) anatomic MR images acquired simultaneously with
the PET data; and (c) fused PET and MRI images showing the precise registration of the 18F uptake in the bones of the jaw and mouth but not
in the adjacent soft tissue. One of the seminal uses of the joint instrumentation will be to unequivocally identify the anatomical locations of the
PET radiotracer by the MRI. (Images courtesy of C. Catana, University of California, Davis; and D. Procissi, California Institute of Technology.)
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mapping glucose metabolism with FDG uptake measure-
ments, while MRI uses vascular response to stimulation
evaluated using changes in blood oxygen level depen-
dent contrast (BOLD). Although there have been many
studies correlating PET and MRI measures of brain
activation [102]–[117], direct simultaneous measure-
ments will provide unequivocal comparisons. PET/MRI
small animal studies with simultaneous bolus IV MRI
contrast agent and H2
15O will provide cross-validation of
CBF measurements.
Fig. 24. In vivo simultaneous PET/MRI: (a) PET images showing FDG uptake in the cortex and Harderian glands; (b) time activity curves
obtained from the brain and Harderian glands showing relative uptake of FDG in two different tissues as a function of time after in injection;
(c) anatomic MR images acquired simultaneously with the PET data; (d) fused PET and MRI images showing the precise registration of
the FDG uptake with anatomic structures. (Images courtesy of C. Catana, University of California, Davis; and D. Procissi,
California Institute of Technology.)
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Sensitivity is the hallmark of the PET methodology,
which has been put to good use in studies of neuroreceptor
distribution and activity with radiolabeled ligands, such as
11C-raclopride, 11C-CFT, and 18F-fluoroDOPA [118]. No
similar studies are possible with MRI due to its intrinsi-
cally low sensitivity, but high-resolution anatomical MR
images provide the context in which to interpret the PET
intensity distributions. Simultaneous PET (neuroreceptor
and FDG) and fMRI BOLD contrast studies will allow
spatial and temporal correlation of biochemical changes
with changes in neuronal activation. Merged data will
combine the fast time scale and sensitivity of PET with the
high spatial resolution of MRI, potentially obviating the
need to average across specimens. Fig. 25 shows results
from a prototype human PET/MRI system where FDG
uptake is shown overlaid on a T2 weighted MRI scan
acquired simultaneously.
C. Mouse Phenotyping
Transgenic rodents are model systems used to address a
vast array of questions about biological mechanisms in
both normal and disease states. It is becoming increasingly
common to use PET and/or MRI to examine the
consequences of altering the genome of an animal
[119]–[123]. Whole-body rodent imaging allows an assess-
ment of structural and physiological alterations across
organ systems in the merged PET/MRI data. Imaging at
various time points will allow assessment of when, as well
as what, and where phenotypic changes are manifest.
Repeated measurements necessitate repeated removal and
replacement of the animal in the imaging system. Although
images recorded at different times will need to be aligned,
employing a joint PET/MRI system completely relieves the
additional burden of repeatedly having to realign images
from the two modalities. Brain activation measures already
discussed will provide detailed information about changes
in the central nervous system (CNS). Mouse models of
neurodegenerative diseases are especially tempting targets
for joint PET/MRI studies, as development of probes and
image acquisition methodologies in preclinical work is
liable to be directly transferable to the clinic. Tissue-
specific metabolic changes can be assessed measuring
whole-body distributions of FDG and correlating this with
31P and 1H MR spectroscopic imaging that provides
information about high-energy phosphate intermediates
(PCr, ATP, ADP, inorganic phosphate) and metabolites
that occur in proton spectroscopy at millimolar levels.
Likewise, bone disease and formation can be followed
using uptake of ionic 18F [124]–[126], which is correlated
to changes in MRI signal intensity [127]. In many
situations, phenotypes change with time (e.g., -amyloid
plaque deposition in Alzheimer’s disease model systems)
and developmental stage (e.g., CNS myelination). The
ability of the PET/MRI systems to repeatedly image the
same animal over time is a significant advantage over
other methodologies where this is not possible, while
simultaneous imaging guarantees image alignment at
each time point. Longitudinal evaluation of the same
animal greatly facilitates evaluation of disease etiology
and progression through characterization of anatomic,
physiological, cellular, and genomic changes.
D. Monitoring Tumor Response
Evaluation of tumor growth characteristics and re-
sponse to therapeutics is essential to gaining a better
understanding of in vivo tumor biology and the mechanism
of action of specific therapeutics. Tumor size, hetero-
geneity, and rate of growth are obvious measures of im-
portance that can be determined with MRI, while tumor
metabolic activity (via FDG uptake) and proliferation (via
accumulation of FLT) can be determined with PET. More
sophisticated MR methodologies can provide information
about tumor vascularity through the use of low molecular
weight contrast agents, as well as tumor necrosis, cell
density, and water mobility using T2 and apparent diffu-
sion coefficient (ADC) maps. Likewise, information about
tumor hypoxia can be obtained with 18F-misonidazole or
64Cu-diacetyl-bis[N4-methylthiosemicarbazone] (ATSM)
while radionuclide-labeled tumor specific antibodies and
peptides are used to detect location(s) of metastasis.
Fig. 25. Simultaneous PET and MR images acquired on a Siemen’s Magnetom Trio MRI equipped with BrainPET insert. From left-to-right:
T2 turbo spin echo (TSE) sequence, FDG PET image, fusion of TSE and PET image, and diffusion EPI sequence. MR and PET data acquired
simultaneously. (Courtesy of D. Townsend and C. Nahmias, University of Tennessee; and H-P Schlemmer et al., University of Tu¨bingen.)
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Although these measurements are informative when
coming from separate imaging sessions, measurements in
the same animal at the same time allow direct identifica-
tion of tumor characteristics revealed in MR images with
physiological and molecular characteristics revealed in
PET images. Registration of PET and MRI brain images has
met with some success [128]–[131]. Because tumors are
often in locations of considerable malleability (e.g.,
abdomen), digital registration of independent PET and
MR images can be very difficult, necessitating simulta-
neous imaging even for simple registration. Reliable
registration at the pixel levels opens up the possibility of
realistic interpretation of MR images (and changes in
them) in terms of the underlying tumor physiology. Thus,
the use of various MR determinations (T1, T2, contrast
enhancement, ADC, metabolite concentration) as
Bbiomarkers[ indicative of changes in the tumor will be
greatly facilitated. While clinical PET scans can be
repeated, there are strict limits to how often, whereas
MRI scans can be performed daily. Having reliable MR
biomarkers that are correlated with known tumor
physiological changes in the preclinical setting would be
a boon to monitoring tumor response to therapeutics and
optimizing treatment on a case-by-case basis. In preclinical
studies, simultaneous imaging will allow assessment of the
distribution of therapeutic agents by high specific activity
radionuclide labeling of the agents, allowing short-term
precise characterization of biodistribution and assessment
of whether the mode of action is direct or indirect.
Longitudinal imaging studies on the minute through week
timescales are often undertaken using tumor model
systems to glean information about mode(s) of action of
potential therapeutics. Such repeated simultaneous PET/
MRI measurements provide temporal as well as spatial
correlation of the two modalities.
Immune system-based therapies in cancer treatment
are aimed at enhancing the body’s own defenses. These
represent a broad array of methodologies that include
targeting of immunological moieties to tumor cells, acti-
vation of T cells, and antigen presentation [132]–[134].
Because these therapies are typically not directly acting,
it is essential to monitor the time course, characteristics,
and specificity of the immune response and its effect
against the tumor. Both PET- and MRI-based procedures
have been proposed to monitor immunotherapies [135],
[136]. In terms of joint PET/MRI measurements, once
again it is the qualitatively different information obtainable
from the two modalities and temporal coincidence that
brings real utility to the simultaneous measurement. PET
agents can be used to efficiently specify the location(s) and
concentration(s) of immune cell populations while mod-
ulation(s) in tumor physiology are monitored with MRI.
Interrogating what is happening to the tumor while the
immune response is being mounted and being able to
correlate tumor changes with the duration and extent of the
response will be of immense help in developing treatment
protocols and in eventually personalizing treatment re-
gimes in the clinic.
The use of dual labeled agents opens up a wealth
of possibilities. For example, the rough location
( millimeters) of small metastasis can be determined
with PET [137], and MR can immediately provide high-
resolution anatomical scans of the suspect region.
Although the concentration of the MR label in a small
metastatic tissue volume may be too low to see in a whole
body survey scan, knowledge of the location of interest
gleaned from the PET image will point to the small
volume(s) from which to record high-resolution MRI data
using a dual labeled probe. Under these more favorable
conditions, the likelihood of seeing contrast enhancement
due to the label is greatly increased (especially for T2
agents). Regardless of the visibility of the label, the high-
resolution MR image will provide an assessment of
anatomical anomalies associated with metastasis and
repeated imaging will allow characterization of the time
course of tumor growth and response to therapeutics from
very early stages.
V. DISCUSSION
Instruments with the ability to simultaneously record
PET and MRI measurements in both small animals and
humans have been developed and are currently being
refined and optimized. At the present time, PET systems
based on APD technology allow existing magnets to be
used and have been studied in most detail. New photon-
detection technologies, especially silicon or solid-state
photomultiplier detectors [138], hold promise for use in
PET/MRI systems with their very robust signals (which
obviates the need to place preamplifiers within the
magnet), fast timing, and low sensitivity to magnetic
fields.
One challenge to the acceptance of PET/MRI, espe-
cially for studies in humans, is attenuation correction of
the PET data. In PET/CT scanners, this correction can be
derived quite directly from the CT data. Although
structural MR images can in theory be segmented into
major tissue types allowing known attenuation coefficients
to be assigned for PET attenuation correction, it is hard to
capture the inhomogeneities in density in regions such as
the lung, and this could cause significant errors in the PET
images. This is an ongoing and important area of
investigation.
Dual-mode contrast agents for PET/MRI hold much
promise but are clearly still in their infancy. Current
efforts are focusing on optimizing the radio-labeling
efficiency of nanoparticle-based probes, evaluating the
toxicity and biodistribution of these novel probes in
animal models, and initial applications, for example, in
imaging of atherosclerotic plaque, using these agents with
the new integrated PET/MRI instrumentation. This
application requires extremely good spatial coregistration
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of the two datasets and will therefore be a good test case
for simultaneous PET/MRI studies.
The future of integrated PET/MRI instruments and/or
dual-mode PET/MRI contrast agents clearly depends on
finding applications (whether these be in basic or clinical
research, preclinical evaluation of therapeutics, or clinical
diagnostics or therapeutic monitoring) that are signifi-
cantly aided by simultaneous PET/MRI strategies. While
some applications, such as those described here, certainly
exist, the complete picture will likely not emerge for
several years as the utility of combined systems becomes
more widely understood. h
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